Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We describe a unique clinical presentation of a child after the acute phase of herpes simplex virus 1 (HSV1) encephalitis. A 17-month-old boy first presented with HSV1 encephalitis and was promptly treated with antiviral medication. Seven months later, he was re-admitted for startle seizures. Magnetic Resonance Imaging of the brain showed diffuse confluent leukoencephalopathy. This constellation of symptoms has not been previously reported in HSV1 encephalitis. In conclusion, we showed that brain injury due to HSV1 encephalitis can be associated with the development of startle seizures and diffuse white matter injury in the post-acute phase.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961350 | PMC |
| http://dx.doi.org/10.1177/2329048X221083761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Misleading Detection of Herpes Simplex Virus Type 1 In A Patient with Paraneoplastic Encephalitis.
Eur J Case Rep Intern Med
August 2025
Division of Internal Medicine, University Hospital of Basel, Basel, Switzerland.
Unlabelled: Encephalitis is a potentially life-threatening condition with infectious or autoimmune aetiologies. Autoimmune encephalitis includes paraneoplastic variants associated with specific onconeural antibodies such as anti-Hu, frequently linked to malignancies. Herpes simplex virus type 1 (HSV-1) is the leading infectious cause in adults.
View Article and Find Full Text PDFBroad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin.
Front Pharmacol
August 2025
Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, United States.
4-Phenylbutyrate (4-PBA), initially recognized for treating urea cycle disorders, has emerged as a potent therapeutic agent with broad-spectrum potential. As a chemical chaperone, 4-PBA modulates protein folding and reduces endoplasmic reticulum stress. 4-PBA has demonstrated efficacy in treating ocular herpes simplex virus type 1 (HSV-1) infection and HSV-1-induced encephalitis, highlighting its potential as a novel anti-herpetic therapy.
View Article and Find Full Text PDFRefractory "status dyskineticus" in a child with post-herpes simplex virus 1 N-methyl-D-aspartate receptor encephalitis: a case report.
BMC Neurol
August 2025
Department of Clinical Pediatrics Sciences, Unit of Child Neuropsychiatry, Member of the ERN Epicare Network, IRCCS Istituto Giannina Gaslini, Via G Gaslini 5, Genova, 16100, Italy.
Background: Herpes simplex virus 1 (HSV-1) encephalitis may result in relapsing neurological symptoms secondary to immune-mediated processes, including anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Refractory status dyskineticus (RSD), a severe subset of status dystonicus, is characterized by a hyperkinetic movement disorder phenotype alongside dystonic features. This critical condition presents substantial challenges in neurocritical care.
View Article and Find Full Text PDFMagnesium Oxide Nanoparticles: A New Frontier in Antiviral Therapy Against Herpes Simplex Virus Type 1.
Adv Virol
August 2025
Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Herpes simplex virus Type 1 (HSV-1) causes a wide spectrum of diseases in humans, including skin and mucosal ulcers, encephalitis, and keratitis. Acyclovir is regarded as the gold standard for treating infections with this virus. However, there are certain drawbacks to using this drug, such as its ineffectiveness against treatment-resistant virus strains.
View Article and Find Full Text PDFGreater Efficacy of Cidofovir Than of Foscarnet for the Treatment of Acyclovir-Resistant Herpes Simplex Virus Infection After Allogeneic Hematopoietic Stem Cell Transplantation.
J Blood Med
August 2025
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, People's Republic of China.
Herpes simplex virus (HSV) infection is a common problem in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Severe HSV infections can cause pneumonia, encephalitis, meningitis and other lesions, thus requiring caution. Acyclovir is the drug of choice for the prevention of HSV infection.
View Article and Find Full Text PDF